Oncternal Therapeutics, Inc. Gains 23.05%

Mon, May 02, 2022 at 05:35 PM

Oncternal Therapeutics, Inc. (ONCT:NASDAQ) soared at $1.05, representing a gain of 23.1%. On Fri, Apr 29, 2022, ONCT:NASDAQ touched a New 2-Week Low of $0.85. The stock got featured on our News Catalysts scanner on Thu, Apr 28, 2022 at 05:26 PM in the 'MISCELLANEOUS' category. From Mon, Apr 18, 2022, the stock recorded 44.44% Up Days and 10.00% Green Days

About Oncternal Therapeutics, Inc. (ONCT:NASDAQ)

GTx Inc is a biopharmaceutical company. It is involved in the business of discovery, development, and commercialization of small molecules for the treatment of cancer including treatment of breast and prostate cancer and other serious medical conditions such as Stress urinary incontinence and Duchenne muscular dystrophy. Its lead product candidate is Enobosarm. The company's strategy is focused on the further development of selective androgen receptor modulators.

Top 10 Gainers:

Better Therapeutics Inc. (BTTX:NASDAQ), 120.39%
SoundHound AI Inc. (SOUN:NASDAQ), 68.46%
Forge Global Holdings Inc. (FRGE:NYSE), 44.34%
Redbox Entertainment Inc. (RDBX:NASDAQ), 42.64%
SOS Limited American Depositary Shares (SOS:NYSE), 39.74%
Blue Apron Holdings, Inc. (APRN:NYSE), 33.77%
Bluejay Diagnostics Inc. (BJDX:NASDAQ), 26.5%
Jasper Therapeutics Inc. (JSPR:NASDAQ), 23.61%
MICT, Inc. (MICT:NASDAQ), 23.19%
Oncternal Therapeutics, Inc. (ONCT:NASDAQ), 23.05%